Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan Safety and Effectiveness in Korean ADPKD Patients
NCT03949894Phase 4Completed
- Sponsor
- Otsuka Holdings
- Start
- Jul 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Otsuka Holdings. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Jul 2019; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT03949894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949894.